Author:
Binder Alison M.,Armstrong Paige A.
Abstract
AbstractRickettsial diseases (RDs) are transmitted to humans by ectoparasites, including ticks and fleas. Symptoms range from mild febrile illness, to severe disease or death. Doxycycline is the treatment of choice for patients of all ages; early treatment based on clinical diagnosis is critical to prevent severe outcomes. We conducted a descriptive analysis using insurance claims data captured by IBM MarketScan® research databases to describe demographics, treatment patterns, and outcomes of patients diagnosed with RDs in the United States during 2005–2017. Overall, 14,830 patients had a RD diagnosis during 2005–2017; 7,517 (50.7%) spotted fever rickettsiosis (SFR), 4,571 ( 30.8%) ehrlichiosis, 1,362 (9.2%) typhus group rickettsiosis (TGR), and 1,193 (8.0%) other rickettsial diseases. Among all patients diagnosed, 53.1% received doxycycline. Prescription rates varied by diagnosis and age; 24.1% of TGR and 61.1% of SFR patients received doxycycline; 23.9% of persons < 8 years received doxycycline, compared with 47.7% for 8–17 years, and 55.4% for ≥ 18 years. RDs are frequently diagnosed in the outpatient population; however, providers prescribed the recommended treatment to about half of patients. Continued education of treatment recommendations is critical to prevent severe outcomes.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2017 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2018. Available at: https://www.cdc.gov/nndss/infectious-tables.html. Accessed 10 September 2019.
2. Wiedeman, C. et al. Knowledge, attitudes, and practices regarding rocky mountain spotted fever among healthcare providers, Tennessee, 2009. Am. J. Trop. Med. Hyg. 88, 162–166 (2013).
3. Dalton, M. J. et al. National surveillance for Rocky Mountain spotted fever, 1981–1992: Epidemiologic summary and evaluation of risk factors for fatal outcome. Am. J. Trop. Med. Hyg. 52, 405–413 (1995).
4. Helmick, C. G., Bernard, K. W. & D’Angelo, L. J. Rocky Mountain spotted fever: Clinical, laboratory, and epidemiological features of 262 cases. J. Infect. Dis. 150, 480–488 (1984).
5. Regan, J. J. et al. Risk factors for fatal outcome from rocky mountain spotted fever in a highly endemic area—Arizona, 2002–2011. Clin. Infect. Dis. 60, 1659–1666 (2015).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献